In the US, a Patient died after a stool transplant. He was in a clinical study, participated in, and succumbed to an infection with a multidrug-resistant strain of the bacterium Escherichia coli. A second Patient, the chair had received from the same donor, was ill, informed the US food and drug administration FDA. The stool sample of the donor was not previously been studied on the resistant strain of the bacterium, and called the name of it.
For healthy humans of the resistant pathogen is usually not dangerous. However, both recipients had received medications that suppress the immune system. So could spread the bacteria, apparently unhindered in the body.
Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research, reported to the New York Times, that an unknown number of similar studies has been stopped. The research should only be resumed if the study could be evidence that the stool samples would be sufficiently scanned for dangerous microorganisms.
In Germany, the security requirements are such studies already “very high,” said Maria Vehreschild of the University of Cologne. She was so “confident” that such complications in Germany could be avoided.
In Germany, a study that examines the use of the “Fecal Microbiota Transplantation” (FMT) for the treatment of an immune response after stem cell transplantation is currently running, according to. “In this study, all donors with regard to the colonization, however, are tested with multi-resistant bacteria and accordingly, are excluded”, stressed Vehreschild.
With fecal transplants, specifically recycled feces from the intestines from a donor into a patient is transplanted. You want the recipient to get in this way a healthy intestinal flora. The method has so far been used, among other things, in the treatment of severe intestinal infections with the bacteria Clostridium difficile to be used.